🍽️ dihydroergotamine tartrate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Migraine Headaches: Dihydroergotamine tartrate is one of the medications commonly used for the acute treatment of migraine headaches. It works by constricting blood vessels in the brain, reducing the pulsatile dilation associated with migraine attacks. Dihydroergotamine may be administered intravenously, intramuscularly, or subcutaneously to provide rapid relief of migraine symptoms, including headache pain, nausea, vomiting, and sensitivity to light and sound.

  2. Cluster Headaches: Dihydroergotamine tartrate may also be used for the acute treatment of cluster headaches, a type of headache characterized by severe, unilateral pain around the eye or temple, often accompanied by autonomic symptoms such as lacrimation (tearing), nasal congestion, and ptosis (drooping eyelid). Dihydroergotamine can help alleviate the intensity and duration of cluster headache attacks when administered promptly during an episode.

  3. Vasoconstrictive Effect: Dihydroergotamine tartrate exerts its therapeutic effects by activating serotonin receptors and causing vasoconstriction (narrowing) of blood vessels, particularly in the cranial circulation. This helps reduce cerebral blood flow and alleviate the throbbing pain associated with migraine and cluster headaches.

  4. Preventive Treatment: In addition to its acute treatment role, dihydroergotamine tartrate may be used as a preventive (prophylactic) therapy for individuals with frequent or severe migraine attacks. It can be administered via intranasal spray or subcutaneous injection on a scheduled basis to reduce the frequency and severity of migraine episodes over time.

  5. Side Effects: Common side effects of dihydroergotamine tartrate may include nausea, vomiting, dizziness, nasal congestion, fatigue, and transient elevations in blood pressure. These side effects are usually mild and transient and may diminish with continued use or dosage adjustments. However, more serious side effects, such as coronary vasospasm, myocardial ischemia, or peripheral ischemia, may occur rarely and require medical attention.

  6. Contraindications: Dihydroergotamine tartrate is contraindicated in individuals with a history of ischemic heart disease, peripheral vascular disease, uncontrolled hypertension, or known hypersensitivity or allergy to ergot alkaloids. It should not be used concurrently with other medications that have vasoconstrictive properties, such as triptans or certain antidepressants, due to the risk of additive effects on blood pressure and cardiovascular function.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of dihydroergotamine tartrate,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by dihydroergotamine tartrate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Odoribacter genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Thomasclavelia genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Phocaeicola genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Segatella genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Roseburia hominis species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Phocaeicola vulgatus species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Bacteroides caccae species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of dihydroergotamine tartrate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0 0
ADHD 1.7 1.7
Age-Related Macular Degeneration and Glaucoma 0.6 0.3 1
Allergic Rhinitis (Hay Fever) 0.7 0.7
Allergies 0.9 0 0
Allergy to milk products 0.3 0.4 -0.33
Alopecia (Hair Loss) 0.8 0.8
Alzheimer's disease 1.6 1.8 -0.13
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.8 0.2 3
Ankylosing spondylitis 1.5 0.5 2
Anorexia Nervosa 0.3 0.7 -1.33
Antiphospholipid syndrome (APS) 0.9 0 0
Asthma 0.4 -0.4
Atherosclerosis 0.2 0.9 -3.5
Atrial fibrillation 1.3 0.6 1.17
Autism 2.5 2.4 0.04
Barrett esophagus cancer 0.2 0.3 -0.5
benign prostatic hyperplasia 0.1 0.1
Biofilm 1.4 1.4
Bipolar Disorder 0.5 0.3 0.67
Brain Trauma 0.4 -0.4
Cancer (General) 0.3 0.5 -0.67
Carcinoma 1.5 1.1 0.36
Celiac Disease 1.3 1.1 0.18
Cerebral Palsy 0.3 0.4 -0.33
Chronic Fatigue Syndrome 1.6 3.4 -1.13
Chronic Kidney Disease 0.7 0.7 0
Chronic Lyme 0.4 -0.4
Chronic Obstructive Pulmonary Disease (COPD) 1.7 0.3 4.67
Chronic Urticaria (Hives) 0.6 0.1 5
Coagulation / Micro clot triggering bacteria 0.8 0.6 0.33
Colorectal Cancer 2.6 0.2 12
Constipation 0.6 0.3 1
Coronary artery disease 0.4 0.4
COVID-19 3.4 5.4 -0.59
Crohn's Disease 2.9 2.1 0.38
cystic fibrosis 0.3 0.4 -0.33
deep vein thrombosis 0.3 0.6 -1
Depression 4.1 2.1 0.95
Dermatomyositis 0.3 0.3
Eczema 0.2 1 -4
Endometriosis 1.3 0.3 3.33
Eosinophilic Esophagitis 0.2 0.2
Epilepsy 0.9 0.4 1.25
Fibromyalgia 1.3 0.5 1.6
Functional constipation / chronic idiopathic constipation 1.2 0.8 0.5
gallstone disease (gsd) 0.7 0.5 0.4
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.7 0.3 1.33
Generalized anxiety disorder 0.6 0.2 2
Glioblastoma 0.3 -0.3
Graves' disease 0.4 0.6 -0.5
Halitosis 0.4 0.3 0.33
Hashimoto's thyroiditis 0.8 0.2 3
Hidradenitis Suppurativa 0.5 0.5
High Histamine/low DAO 0.5 0.5
hypercholesterolemia (High Cholesterol) 0.3 0.3
hyperglycemia 0.1 0.4 -3
hypersomnia 0 0
hypertension (High Blood Pressure 0.8 2.2 -1.75
Hypoxia 0.4 0.4
IgA nephropathy (IgAN) 0.9 -0.9
Inflammatory Bowel Disease 2.1 1.8 0.17
Insomnia 0.5 0.4 0.25
Intelligence 0.4 0 0
Intracranial aneurysms 0.4 0.4
Irritable Bowel Syndrome 1.3 1.4 -0.08
Liver Cirrhosis 2 1.1 0.82
Long COVID 3.1 2.2 0.41
Low bone mineral density 0.3 -0.3
Lung Cancer 0.3 0.3 0
Mast Cell Issues / mastitis 0.4 0.4
ME/CFS with IBS 0.3 0.8 -1.67
ME/CFS without IBS 0.6 1.6 -1.67
Metabolic Syndrome 2.6 3.3 -0.27
Mood Disorders 4.1 2.1 0.95
multiple chemical sensitivity [MCS] 0.9 0.9
Multiple Sclerosis 2.3 2.2 0.05
Multiple system atrophy (MSA) 1.2 1.2
neuropathic pain 0.7 -0.7
Neuropathy (all types) 0.3 0.1 2
neuropsychiatric disorders (PANDAS, PANS) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.7 0.9 -0.29
Obesity 3.6 2.2 0.64
obsessive-compulsive disorder 1.8 1.2 0.5
Osteoarthritis 1.2 1.2
Osteoporosis 0.3 0.2 0.5
pancreatic cancer 0.6 0.6
Parkinson's Disease 0.8 1.2 -0.5
Polycystic ovary syndrome 0.9 0.6 0.5
Premenstrual dysphoric disorder 0.3 -0.3
primary biliary cholangitis 0.3 0.4 -0.33
Psoriasis 1.2 1.3 -0.08
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2 1.4 0.43
Rosacea 0.3 -0.3
Schizophrenia 1.1 0.3 2.67
scoliosis 0 0
Sjögren syndrome 1 1.3 -0.3
Sleep Apnea 0.2 0.4 -1
Slow gastric motility / Gastroparesis 0.3 0.3
Small Intestinal Bacterial Overgrowth (SIBO) 0.7 0.7
Stress / posttraumatic stress disorder 1.4 0.4 2.5
Systemic Lupus Erythematosus 1.6 0.6 1.67
Tic Disorder 0.7 0.3 1.33
Tourette syndrome 0.2 -0.2
Type 1 Diabetes 0.7 0.9 -0.29
Type 2 Diabetes 2.9 3 -0.03
Ulcerative colitis 1.2 1.8 -0.5
Unhealthy Ageing 1.7 1 0.7

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]